Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

Coronavirus (COVID-19) Clinical Trial

Official title:

Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04445610
• Other study ID #: FMASU P31a/ 2020
• Status: Not yet recruiting
• Start date: July 1, 2020
• Est. completion date: November 1, 2020

Study information

• Verified date: June 2020
• Source: Ain Shams University
• Contact: Amira Al Balakosy, MD
• Phone: 01221977455
• Email: drbalakosy[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

Description:

Objectives:

1. To identify Measles IgG titre in SARS-COV2 infected patients .

2. correlate level of Measles IgG titre with the clinical severity of COVID-19 disease.

Secondary Objective To find an association of the postulated protective role of measles vaccine and SARS-COV2 infection

Criteria:

Inclusion criteria:included patients would be divided into 3 groups according to clinical severity of COVID-19 disease (mild ,moderate & severe)

• All patients with confirmed COVID 19 confirmed by positive PCR . .

• Any age or gender.

Exclusion criteria:

• Any patient refusing to be involved in the study.

Methods:

• Informed consent will be taken from each subject

• Full clinical examination.

• Evaluation of Measles Antibody Titer:

The measles virus IgG antibody titer will be determined quantitatively by ELISA for quantitative determination of IgG class antibodies against Measles virus in human serum or plasma (citrate, heparin).

• Anonymous data will be retrieved from the admitted patients' files, such as:

• CBC, CRP, AST, ALT, ESR, Serum ferritin & SARS CoV 2 RNA PCR swab results.

• Chest X ray and/or CT chest.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: November 1, 2020
• Est. primary completion date: September 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients with confirmed COVID 19.

• Any age or gender

Exclusion Criteria:

• - Any patient refusing to be involved in the study

Related Conditions & MeSH terms

• Coronavirus (COVID-19)
• Measles

Locations

Country	Name	City	State
Egypt	Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center	Cairo	Non-US

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Viral clearance	Achievement of two consecutive negative PCR results for COVID 19 and discharge from hospital	6 months